Innovation
Share your love
FDA approves NDA labeling supplement allowing re-administration of iDose TR | Ophthalmology Times
The US Food and Drug Administration has approved an NDA labeling supplement from Glaukos enabling the re-administration of iDose TR (travoprost intracameral implant) using a repeat treatment protocol. According to the company, under the updated labeling for iDose TR, physicians may now re-administer iDose…
Opus Genetics launches phase 1/2 MERTK gene therapy trial | Ophthalmology Times
(Image Credit: AdobeStock/Dragon Claws) Opus Genetics has launched its clinical trial evaluating OPGx-MERTK gene therapy for MERTK-related retinitis pigmentosa (RP). The trial is funded through Abu Dhabi’s Healthcare Research and Innovation Fund. OPGx-MERTK is an investigational adeno-associated virus (AAV)-based gene…
Myra Vision treats first patient in ADAPT trial of Calibreye TGT Surgical System | Ophthalmology Times
(Image Credit: AdobeStock/andrew_shots) Myra Vision has treated the first patient in its ADAPT clinical study evaluating the Calibreye TGT Surgical System in patients with glaucoma. The ADAPT trial is a prospective, multicenter, nonrandomized, open-label study enrolling 70 refractory glaucoma patients…
Dr. Mali’s top 5 predictions in ophthalmology for 2026 | Ophthalmology Times
From artificial intelligence to retinal care and postoperative protection, Joshua Mali, MD, FASRS, offers five predictions shaping ophthalmology in 2026. (Image credit: AdobeStock/Sam Efendi) It’s that exciting time of the year again when I reveal my top 5 predictions in…
Rayner announces Sophi Phaco System in the US | Ophthalmology Times
The FDA has given 501(k) clearance to Rayner’s Sophi (Swiss Ophthalmology Innovation) Phacoemulsification System, making it available to cataract surgeons in the US, according to the company.1 The platform was designed with a focus on mobility, simplicity, and safety, which…
FDA clears first daily disposable EDOF contact lens for presbyopia | Ophthalmology Times
The US FDA has officially cleared the first and only daily disposable soft (hydrophilic) contact lens for presbyopia that utilizes patented Extended Depth of Focus (EDOF) optical design technology.1 The Cataltheia Group and its US subsidiary Bruno Vision Care stated…
Exploring Emerging Therapies in the Retinal Vascular Disease Pipeline | Ophthalmology Times
The final segment highlights the rapidly evolving pipeline of retinal vascular disease therapies and offers closing reflections from the panelists. The discussion emphasizes the promise of next-generation agents, including sustained-release implants, tyrosine kinase inhibitors (TKIs), and gene therapies. TKIs are…
Glaucoma innovation: Eight themes to watch in 2026 | Ophthalmology Times
Glaucoma care is evolving through the integration of artificial intelligence, advanced procedures, and personalized treatment strategies. (Image credit: AdobeStock/thodonal) As the ophthalmology community observes Glaucoma Awareness Month this January, glaucoma specialists point to incremental integration of technologies that support earlier…
What changed in glaucoma care in 2025: Surgeon perspective | Ophthalmology Times
In a year-end conversation, Oluwatosin U. Smith, MD, of Glaucoma Associates of Texas, in Dallas, sat down with the Eye Care Network to reflect on how glaucoma care evolved as 2025 drew to a close. Framing the discussion as a…
Global trial equity: How LMIC data is reshaping US ophthalmology research | Ophthalmology Times
Incorporating data from low- and middle-income countries may help redefine how ophthalmology trials are designed, evaluated, and applied in practice (Image credit: AdobeStock/PUTRABATARA) Innovation in ophthalmology is often measured by what reaches the clinic—but the path to those breakthroughs begins…